What is he best known for?
The fields of study he is best known for:
Carlo M. Croce mainly investigates Molecular biology, Chromosomal translocation, Genetics, Gene and Chromosome.
His Molecular biology research is multidisciplinary, incorporating elements of Cell culture, Karyotype, Antigen, Locus and Chromosome 7.
His Cell culture research is multidisciplinary, incorporating perspectives in In vitro and Antibody, Monoclonal antibody.
His Chromosomal translocation research includes elements of B cell and Chromosome 17.
His study in Cytogenetics and Molecular cloning is carried out as part of his Gene studies.
The Chromosome study which covers In situ hybridization that intersects with Pathogenesis, Tumour antigen, Gene mapping and Metaphase.
His most cited work include:
- Molecular cloning of a new transforming gene from a chemically transformed human cell line (825 citations)
- Method of producing antibodies (437 citations)
- Localization of gene for human p53 tumour antigen to band 17p13 (396 citations)
What are the main themes of his work throughout his whole career to date?
Carlo M. Croce focuses on Molecular biology, Genetics, Gene, Chromosomal translocation and Chromosome.
His studies deal with areas such as Cell culture, Locus, Chromosome 22, Antibody and Chromosome 7 as well as Molecular biology.
His Locus research includes themes of Alpha chain and Gene rearrangement.
His Chromosome 22 study incorporates themes from Chromosome 21 and breakpoint cluster region.
His study connects Cancer research and Gene.
His Chromosomal translocation study integrates concerns from other disciplines, such as Immunoglobulin light chain, T-cell receptor, B cell and Lymphoma.
He most often published in these fields:
- Molecular biology (58.40%)
- Genetics (32.82%)
- Gene (32.82%)
What were the highlights of his more recent work (between 1998-2020)?
- microRNA (5.73%)
- Cancer research (11.45%)
- Internal medicine (4.20%)
In recent papers he was focusing on the following fields of study:
Carlo M. Croce mostly deals with microRNA, Cancer research, Internal medicine, Control sample and Cancer.
His microRNA study results in a more complete grasp of Gene.
The study incorporates disciplines such as STIM1 and Cell growth in addition to Gene.
As part of the same scientific family, Carlo M. Croce usually focuses on Cancer research, concentrating on DNA methylation and intersecting with Methylation, Cell and Carcinoma.
His work in the fields of Internal medicine, such as Lymphocytic leukaemia and Disease, overlaps with other areas such as In patient and Statement.
The subject of his Chronic lymphocytic leukemia research is within the realm of Genetics.
Between 1998 and 2020, his most popular works were:
- Correction: Chronic lymphocytic leukaemia (60 citations)
- Exon structure and promoter identification of STIM1 (alias GOK), a human gene causing growth arrest of the human tumor cell lines G401 and RD. (45 citations)
- E2F1-Regulated MicroRNAs Impair TGFb-Dependent Cell-Cycle Arrest and Apoptosis in Gastric Cancer (30 citations)
In his most recent research, the most cited papers focused on:
His scientific interests lie mostly in microRNA, Cancer research, Cancer, Computational biology and Internal medicine.
His work deals with themes such as Bladder cancer, DNA microarray, Gene expression, Neoplastic transformation and Pathology, which intersect with microRNA.
His research in Cancer research intersects with topics in Hematologic malignancy, Cohort and Somatic cell.
His Cancer study combines topics from a wide range of disciplines, such as Apoptosis, Gene product and E2F1.
The various areas that Carlo M. Croce examines in his Computational biology study include DNA, Identification, Bioinformatics and Expression data.
In general Internal medicine study, his work on Lymphocytic leukaemia, Overall survival, Disease and Ibrutinib often relates to the realm of Statement, thereby connecting several areas of interest.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
